Posters

The perspective study: use of cyclosporine A 0.1% eye drop emulsion in patients with dry eye disease and severe keratitis in the real-world setting – patient demographics and baseline characteristics

Poster Details

First Author: G.Geerling GERMANY

Co Author(s):    S. Hamada   S. Trocmé   S. Ræder   C. Fassari   I. Lanzl        

Abstract Details

Purpose:

The PERSPECTIVE study evaluated (in routine clinical practice) the effectiveness, tolerability and safety of cyclosporine A 0.1% (CsA) eye drop emulsion in controlling severe keratitis in adult dry eye patients who have not improved despite treatment with tear substitutes. The data presented here provide a summary of the final study population demographics and clinical characteristics at baseline.

Setting:

A 12-month, European, non-interventional, multicentre, prospective study of adults (aged above 18 years) with dry eye disease (DED) and severe keratitis attending 44 ophthalmology clinics based in Finland, Germany, Norway, Sweden and the UK.

Methods:

Baseline data were collected for adults with DED and severe keratitis included in the PERSPECTIVE study. All participants were currently treated with artificial tears (ATs). Subjects were excluded if they were previously or currently treated with CsA eye drop emulsion or immunosuppressants (within 6 months), had undergone ophthalmic surgery or were pregnant. Baseline measures comprised sex, age, associated systemic disease, previous steroid use and frequency of AT use. Reported clinical signs included corneal fluorescein staining (CFS assessed by Oxford grade scale), Schirmer's test and tear breakup time (TBUT). Subjective symptoms and reasons for changing to CsA therapy were recorded.

Results:

The study included 471 subjects; 75.8% were female. Mean age (SD) was 61.9 (15.41) years. Associated systemic conditions included rheumatologic disease (13.8%) and primary Sjögren syndrome (8.7%). Previous steroid use was 7.6% and 48.4% administered ATs at least twice daily. Approximately 5.6% reported severe eyelid erythema and 6.3% had severe conjunctival erythema. CFS score was typically grades II (33.0%) and III (32.6%). Median (IQR) Schirmer's test was 6.0 (12.0) mm. Median (IQR) TBUT was 4.0 (2.0) seconds. Foreign body sensation and stinging were severe for 18.3% and 14.3%, respectively. Insufficient disease control was the main reason for initiating CsA therapy.

Conclusions:

Participants included in the PERSPECTIVE study population represent DED and severe keratitis patients that may seek treatment from ophthalmology clinics in the real-world setting. The reported population is typically female and approximately 60 years of age. Severe clinical signs and subjective symptoms are observed in relatively few patients. AT use is frequent and insufficient disease control is the main reason for initiating CsA eye drop emulsion treatment. When available, the results will provide information on the effectiveness, tolerability and safety of CsA eye drop emulsion in controlling DED with severe keratitis in routine clinical practice.

Financial Disclosure:

is employed by a for-profit company with an interest in the subject of the presentation, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented